Bioverge The Bioverge Podcast
-
- Business
-
Join Neil Littman on The Bioverge Podcast as he explores the intersection of bio x tech and features the entrepreneurs, investors, and industry leaders who are revolutionizing healthcare and bringing science fiction to life.
-
Decoding Biotech: A Deep Dive into AI and Platform Technologies
Kiersten Stead, Co-Founder and Managing Partner of DCVC Bio sits down with Neil to discuss her firm’s approach to deep tech investing in biotech, her focus on platform technologies, and how to separate what’s real from what’s hype in AI
-
Financing Biotech: Portfolio Theory and Netflix-Inspired Models
Andrew Lo, Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management, sits down with Neil to discuss his application of portfolio theory to address the challenges of funding drug development and how a Netflix subscription model can address the coming crisis in funding high-priced curative therapies approaching the market.
-
Bringing A Hub-and-Spoke Business Model to Regenerative Medicine
Faizzan Ahmad, Co-Founder and CEO of Cure8bio, sits down with Neil to discuss its growing portfolio of regenerative medicines in development, its hub-and-spoke business model designed to leverage resources and reduce risk, and its push toward curative therapies.
-
Enlisting Liquid Biopsies in the Fight Against Chronic Diseases
Nathan Hunkapiller, Chief Scientific Officer and Co-Founder of Curve Biosciences, sits down with Neil to discuss liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of chronic diseases, and how it is enabling earlier intervention.
-
Developing Targeted Therapies to Address Heart Failure
Drew Titmarsh, Co-Founder and CEO of Dynomics, sits down with Neil to discuss that lack of innovative therapies to treat heat disease, the company’s discovery platform that uses engineered cardiac organoids that function like adult human heart tissue, and how the company is using this to develop precision therapies to address the root causes of heart failure.
-
Speeding Drug Development by Unlocking the Mechanism of Action of Cancer Therapies
David Li, Co-Founder and CEO of Meliora Therapeutics, sits down with Neil to discuss why the mechanism of action for cancer therapies in development is poorly understood, how this leads to a high and costly clinical failure rate, and how Meliora's platform technology uncovers the true mechanism of action of a drug and it enables it to identify promising drug scaffolds to accelerate the development process.
Customer Reviews
Best biotech pod out there
This one is a must-listen for deep dives on the latest biotech and healthcare co’s.